Cargando…

Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H

BACKGROUND: [(18)F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation dosimetry of [(18)F]UCB-H in a preclinical trial and to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bretin, Florian, Warnock, Geoffrey, Bahri, Mohamed Ali, Aerts, Joël, Mestdagh, Nathalie, Buchanan, Tim, Valade, Anne, Mievis, Frédéric, Giacomelli, Fabrice, Lemaire, Christian, Luxen, André, Salmon, Eric, Seret, Alain, Plenevaux, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655042/
https://www.ncbi.nlm.nih.gov/pubmed/23647774
http://dx.doi.org/10.1186/2191-219X-3-35
_version_ 1782269820152053760
author Bretin, Florian
Warnock, Geoffrey
Bahri, Mohamed Ali
Aerts, Joël
Mestdagh, Nathalie
Buchanan, Tim
Valade, Anne
Mievis, Frédéric
Giacomelli, Fabrice
Lemaire, Christian
Luxen, André
Salmon, Eric
Seret, Alain
Plenevaux, Alain
author_facet Bretin, Florian
Warnock, Geoffrey
Bahri, Mohamed Ali
Aerts, Joël
Mestdagh, Nathalie
Buchanan, Tim
Valade, Anne
Mievis, Frédéric
Giacomelli, Fabrice
Lemaire, Christian
Luxen, André
Salmon, Eric
Seret, Alain
Plenevaux, Alain
author_sort Bretin, Florian
collection PubMed
description BACKGROUND: [(18)F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation dosimetry of [(18)F]UCB-H in a preclinical trial and to determine the maximum injectable dose according to guidelines for human biomedical research. The radiation dosimetry was derived by organ harvesting and dynamic micro positron emission tomography (PET) imaging in mice, and the results of both methods were compared. METHODS: Twenty-four male C57BL-6 mice were injected with 6.96 ± 0.81 MBq of [(18)F]UCB-H, and the biodistribution was determined by organ harvesting at 2, 5, 10, 30, 60, and 120 min (n = 4 for each time point). Dynamic microPET imaging was performed on five male C57BL-6 mice after the injection of 9.19 ± 3.40 MBq of [(18)F]UCB-H. A theoretical dynamic bladder model was applied to simulate urinary excretion. Human radiation dose estimates were derived from animal data using the International Commission on Radiological Protection 103 tissue weighting factors. RESULTS: Based on organ harvesting, the urinary bladder wall, liver and brain received the highest radiation dose with a resulting effective dose of 1.88E-02 mSv/MBq. Based on dynamic imaging an effective dose of 1.86E-02 mSv/MBq was calculated, with the urinary bladder wall and liver (brain was not in the imaging field of view) receiving the highest radiation. CONCLUSIONS: This first preclinical dosimetry study of [(18)F]UCB-H showed that the tracer meets the standard criteria for radiation exposure in clinical studies. The dose-limiting organ based on US Food and Drug Administration (FDA) and European guidelines was the urinary bladder wall for FDA and the effective dose for Europe with a maximum injectable single dose of approximately 325 MBq was calculated. Although microPET imaging showed significant deviations from organ harvesting, the Pearson’s correlation coefficient between radiation dosimetry derived by either method was 0.9666.
format Online
Article
Text
id pubmed-3655042
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-36550422013-05-16 Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H Bretin, Florian Warnock, Geoffrey Bahri, Mohamed Ali Aerts, Joël Mestdagh, Nathalie Buchanan, Tim Valade, Anne Mievis, Frédéric Giacomelli, Fabrice Lemaire, Christian Luxen, André Salmon, Eric Seret, Alain Plenevaux, Alain EJNMMI Res Original Research BACKGROUND: [(18)F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation dosimetry of [(18)F]UCB-H in a preclinical trial and to determine the maximum injectable dose according to guidelines for human biomedical research. The radiation dosimetry was derived by organ harvesting and dynamic micro positron emission tomography (PET) imaging in mice, and the results of both methods were compared. METHODS: Twenty-four male C57BL-6 mice were injected with 6.96 ± 0.81 MBq of [(18)F]UCB-H, and the biodistribution was determined by organ harvesting at 2, 5, 10, 30, 60, and 120 min (n = 4 for each time point). Dynamic microPET imaging was performed on five male C57BL-6 mice after the injection of 9.19 ± 3.40 MBq of [(18)F]UCB-H. A theoretical dynamic bladder model was applied to simulate urinary excretion. Human radiation dose estimates were derived from animal data using the International Commission on Radiological Protection 103 tissue weighting factors. RESULTS: Based on organ harvesting, the urinary bladder wall, liver and brain received the highest radiation dose with a resulting effective dose of 1.88E-02 mSv/MBq. Based on dynamic imaging an effective dose of 1.86E-02 mSv/MBq was calculated, with the urinary bladder wall and liver (brain was not in the imaging field of view) receiving the highest radiation. CONCLUSIONS: This first preclinical dosimetry study of [(18)F]UCB-H showed that the tracer meets the standard criteria for radiation exposure in clinical studies. The dose-limiting organ based on US Food and Drug Administration (FDA) and European guidelines was the urinary bladder wall for FDA and the effective dose for Europe with a maximum injectable single dose of approximately 325 MBq was calculated. Although microPET imaging showed significant deviations from organ harvesting, the Pearson’s correlation coefficient between radiation dosimetry derived by either method was 0.9666. Springer 2013-05-07 /pmc/articles/PMC3655042/ /pubmed/23647774 http://dx.doi.org/10.1186/2191-219X-3-35 Text en Copyright ©2013 Bretin et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Bretin, Florian
Warnock, Geoffrey
Bahri, Mohamed Ali
Aerts, Joël
Mestdagh, Nathalie
Buchanan, Tim
Valade, Anne
Mievis, Frédéric
Giacomelli, Fabrice
Lemaire, Christian
Luxen, André
Salmon, Eric
Seret, Alain
Plenevaux, Alain
Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H
title Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H
title_full Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H
title_fullStr Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H
title_full_unstemmed Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H
title_short Preclinical radiation dosimetry for the novel SV2A radiotracer [(18)F]UCB-H
title_sort preclinical radiation dosimetry for the novel sv2a radiotracer [(18)f]ucb-h
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655042/
https://www.ncbi.nlm.nih.gov/pubmed/23647774
http://dx.doi.org/10.1186/2191-219X-3-35
work_keys_str_mv AT bretinflorian preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT warnockgeoffrey preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT bahrimohamedali preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT aertsjoel preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT mestdaghnathalie preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT buchanantim preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT valadeanne preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT mievisfrederic preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT giacomellifabrice preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT lemairechristian preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT luxenandre preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT salmoneric preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT seretalain preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh
AT plenevauxalain preclinicalradiationdosimetryforthenovelsv2aradiotracer18fucbh